Literature DB >> 21131840

The fallopian tube-peritoneal junction: a potential site of carcinogenesis.

Jeffrey D Seidman1, Anna Yemelyanova, Richard J Zaino, Robert J Kurman.   

Abstract

Junctions between different types of epithelia are hot spots for carcinogenesis, but the junction of the peritoneal mesothelium with the fallopian tubal epithelium, the tubal-peritoneal junction, has not been characterized earlier. A total of 613 junctional foci in 228 fallopian tube specimens from 182 patients who underwent surgery for a variety of indications, including 27 risk-reducing salpingo-oophorectomy specimens, were studied. Edema, congestion, and dilated lymphatic channels were commonly present. Transitional metaplasia was found at the junction in 20% of patients and mesothelial hyperplasia in 17%. Inflammation at the junction was seen predominantly in patients with salpingitis, torsion, or tubal pregnancy. Ovarian-type stroma was found at the junction in 5% of patients, and was found elsewhere in the tubal lamina propria in an additional 27% of patients. Findings in risk-reducing salpingo-oophorectomy specimens in women with BRCA mutations, a personal history of breast cancer, and/or a family history of breast/ovarian cancer were similar to those in controls. Transitional metaplasia specifically localizes to this junction, and is the probable source of Walthard cell nests. The recently highlighted significance of fimbrial tubal epithelium in the origin of serous ovarian carcinomas and a study suggesting that mucinous and Brenner tumors may arise from transitional-type epithelium in this location suggest that the tubal-peritoneal junction may play a role in the development of these tumors. This is the first comprehensive description of a hitherto unrecognized transitional zone in the adnexa.

Entities:  

Mesh:

Year:  2011        PMID: 21131840     DOI: 10.1097/PGP.0b013e3181f29d2a

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  23 in total

1.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

2.  The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.

Authors:  Elisabetta Kuhn; Ayse Ayhan; Ie-Ming Shih; Jeffrey D Seidman; Robert J Kurman
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

3.  Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Britton Trabert; Megan A Murphy; Mark E Sherman; Joshua N Sampson; Louise A Brinton; Patricia Hartge; Albert Hollenbeck; Yikyung Park; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-11-10       Impact factor: 7.396

Review 4.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

5.  The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.

Authors:  Gang Ning; Jonathan G Bijron; Yusuke Yamamoto; Xia Wang; Brooke E Howitt; Michael Herfs; Eric Yang; Yue Hong; Maxence Cornille; Lingyan Wu; Suchanan Hanamornroongruang; Frank D McKeon; Christopher P Crum; Wa Xian
Journal:  J Pathol       Date:  2014-09-30       Impact factor: 7.996

6.  Mode of Referral of Ovarian Cancer Patients: Does it Alter Treatment and Survival?

Authors:  Anas Barakat; Aemn Ismail; Quentin Davies; Supratik Chattopadhyay
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

7.  Inhibitory role of prohibitin in human ovarian epithelial cancer.

Authors:  Lin Jia; Jian-Min Ren; Yi-Ying Wang; Yu Zheng; Hui Zhang; Qing Zhang; Bei-Hua Kong; Wen-Xin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma.

Authors:  M Herman Chui; Yihong Wang; Ren-Chin Wu; Jeffrey Seidman; Robert J Kurman; Tian-Li Wang; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

9.  Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

Authors:  Jinghong Jiang; Di Bo; Xiaohong Chang; Hongyan Cheng; Xue Ye; Heng Cui
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  The new face of ovarian cancer modeling: better prospects for detection and treatment.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  F1000 Med Rep       Date:  2011-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.